Evidence map›Paper›PMID 38791464›Full record

SynthesisInternational journal of molecular sciences2024

Systematic Review of Genetic Modifiers Associated with the Development and/or Progression of Nephropathy in Patients with Sickle Cell Disease.

Veerle Labarque, Emmanuel Chide Okocha, International Hemoglobinopathy Research Network (INHERENT)

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Genetics and Genomics in Sickle Cell Disease in Africa.American journal of hematology · 2026
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Veerle LabarqueDepartment of Pediatric Hemato-Oncology, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-5052-9274
Emmanuel Chide OkochaHaematology Department, Faculty of Basic Clinical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi PMB 5025, Anambra State, Nigeria.
International Hemoglobinopathy Research Network (INHERENT)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell nephropathy (SCN) is a common complication of sickle cell disease (SCD) that significantly contributes to morbidity and mortality. In addition to clinical and life-style factors, genetic variants influence this risk. We performed a systematic review, searching five databases. Studies evaluating the effect of genetic modifiers on SCN were eligible. Twenty-eight studies (fair-to-good quality) were included: one genome-wide association study, twenty-six case-control studies, and one article combining both approaches.

Indexed as

Anemia, Sickle CellGenome-Wide Association StudyApolipoprotein L1Disease ProgressionGenes, ModifierGenetic Predisposition to DiseaseGlomerular Filtration RateHumansKidney DiseasesAPOL1 protein, humanApolipoprotein L1acidification deficitalbuminuriadecreased glomerular filtrationhyposthenuriakidney failurenephropathysickle cell disease

Identifiers

PMID38791464
PMCPMC11121490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.